BIO-TECHNE TO PRESENT AT THE KEYBANC LIFE SCIENCES & MEDTECH INVESTOR FORUM
Werte in diesem Artikel
MINNEAPOLIS, March 12, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Will Geist, President, Protein Sciences Segment, will present at the KeyBanc Life Sciences & MedTech Investor Forum on Tuesday, March 19, 2024, at 9:45 a.m. EDT. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.
About Bio-Techne (NASDAQ: TECH)
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated over $1.1 billion in net sales in fiscal 2023 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit http://www.bio-techne.com or follow the Company on social media at Facebook, LinkedIn, Twitter or YouTube.
Contact: | David Clair, Vice President, Investor Relations & Corporate Development | |
612-656-4416 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-to-present-at-the-keybanc-life-sciences--medtech-investor-forum-302086247.html
SOURCE Bio-Techne Corporation
Ausgewählte Hebelprodukte auf Bio-Techne
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Bio-Techne
Der Hebel muss zwischen 2 und 20 liegen
Aktuelle Bio-Techne Aktie News
Bio-Techne Analysen
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Bio-Techne nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen
| Datum | Rating | Analyst | |
|---|---|---|---|
| 31.10.18 | Bio-Techne Hold | Craig Hallum | |
| 18.01.17 | Bio-Techne Buy | Deutsche Bank AG | |
| 21.01.15 | Bio-Techne Outperform | Robert W. Baird & Co. Incorporated |
